Associated Papers
Spectral Profiling of Early αsyn Aggregation in HEK293 Cells Modified to Stably Express Human WT and A53T-αsyn.
Swaminathan P et al.
Cells, 2025
Cholesterol-mediated Lysosomal Dysfunction in APOE4 Astrocytes Promotes α-Synuclein Pathology in Human Brain Tissue.
Mesentier-Louro LA et al.
Biorxiv : the Preprint Server for Biology, 2025
G6PD deficiency triggers dopamine loss and the initiation of Parkinson's disease pathogenesis.
Stykel MG et al.
Cell Reports, 2025
α-Synuclein-dependent increases in PIP5K1γ drive inositol signaling to promote neurotoxicity.
Horvath JD et al.
Cell Reports, 2023
Interaction Between the Glymphatic System and α-Synuclein in Parkinson's Disease.
Zhang Y et al.
Molecular Neurobiology, 2023
Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models.
Chin RM et al.
Biorxiv : the Preprint Server for Biology, 2023
Generation of an induced pluripotent stem cell line (EURACi014-A) from a Parkinson's disease patient with an A53T mutation in the SNCA gene by an integration-free reprogramming method.
Gilmozzi V et al.
Stem Cell Research, 2022
Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease.
Bi M et al.
Redox Biology, 2021
Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction.
Yu Z et al.
Brain : a Journal of Neurology, 2020
Pathogenic Mutations Differentially Regulate Cell-to-Cell Transmission of α-Synuclein.
Guan Y et al.
Frontiers in Cellular Neuroscience, 2020
GBA RNAi but not catalytic inhibition of glucocerebrosidase with Conduritol-β-epoxide increases levels of total α-synuclein in SH-SY5Y cells.
Zurbruegg M et al.
Neuroscience Letters, 2019
The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model.
Katt ME et al.
Fluids and Barriers of the Cns, 2019
Replication of multiple system atrophy prions in primary astrocyte cultures from transgenic mice expressing human α-synuclein.
Krejciova Z et al.
Acta Neuropathologica Communications, 2019
Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions.
Tsigelny IF et al.
Acs Chemical Neuroscience, 2015
Genetic variants and animal models in SNCA and Parkinson disease.
Deng H et al.
Ageing Research Reviews, 2014
Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.
Oaks AW et al.
Plos One, 2013
Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells.
Tehranian R et al.
Journal of Neurochemistry, 2006
Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V et al.
Neurochemistry International, 2006
Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro.
Lehmensiek V et al.
Neuroreport, 2002